

Giulia Siravegna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5809216/publications.pdf>

Version: 2024-02-01

34
papers

13,114
citations

159585

30
h-index

361022

35
g-index

35
all docs

35
docs citations

35
times ranked

18578
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	12.4	3,665
2	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , 2012, 486, 532-536.	27.8	1,605
3	Integrating liquid biopsies into the management of cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 531-548.	27.6	1,375
4	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	30.7	809
5	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	10.7	778
6	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. <i>Nature Medicine</i> , 2016, 22, 262-269.	30.7	768
7	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Cancer Discovery</i> , 2013, 3, 658-673.	9.4	585
8	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	27.8	480
9	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	9.4	384
10	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 147-153.	9.4	338
11	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 36-44.	9.4	258
12	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Science Translational Medicine</i> , 2014, 6, 224ra26.	12.4	228
13	Emergence of Multiple <i>EGFR</i> Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2157-2166.	7.0	227
14	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016, 7, 13665.	12.8	170
15	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in <i>MET</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2015, 5, 1271-1281.	9.4	162
16	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	7.0	148
17	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1994-1999.	1.2	105
18	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal Cancer. <i>Cancer Research</i> , 2016, 76, 4504-4515.	0.9	91

#	ARTICLE	IF	CITATIONS
19	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 963-971.	9.4	85
20	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. <i>Science Translational Medicine</i> , 2016, 8, 324ra14.	12.4	81
21	Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. <i>Genome Biology</i> , 2014, 15, 449.	8.8	77
22	Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 2652.	3.7	71
23	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3260-3267.	7.0	62
24	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	7.0	53
25	Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. <i>Molecular Oncology</i> , 2016, 10, 475-480.	4.6	52
26	Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. <i>Stem Cells</i> , 2017, 35, 2218-2228.	3.2	47
27	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 80-83.	2.3	40
28	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , 2017, 28, 1302-1308.	1.2	32
29	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 347-352.	6.4	31
30	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. <i>Clinical Colorectal Cancer</i> , 2019, 18, 91-101.e3.	2.3	29
31	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , 2019, 4, e000572.	4.5	27
32	Liquid biopsies to evaluate early therapeutic response in colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1525-1527.	1.2	19
33	Minimal Residual Disease in Breast Cancer: In Blood Veritas. <i>Clinical Cancer Research</i> , 2014, 20, 2505-2507.	7.0	14
34	Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, 157-159.	1.2	6